Protagonist Therapeutics Inc (PTGX)
Debt-to-equity ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 675,295 | 531,915 | 541,324 | 560,444 | 336,677 | -643,045 | 294,068 | -570,480 | -536,755 | 243,616 | 267,978 | 301,778 | -409,362 | 329,660 | 357,447 | 259,334 | -283,811 | 169,590 | 167,485 | 62,666 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $675,295K
= 0.00
The debt-to-equity ratio of Protagonist Therapeutics Inc over the past few years has been consistently low, with a ratio of 0.00 or not applicable for most of the reported periods. This indicates that the company has very little or no debt relative to its equity, suggesting a low level of financial risk as the company is primarily funded through its equity investments rather than borrowing. A low debt-to-equity ratio is generally seen as favorable as it implies that the company is not overly reliant on debt financing to operate its business. It also signifies a strong financial position, as the company has more flexibility in managing its operations and financial obligations without the burden of high debt levels.
Peer comparison
Dec 31, 2024